Rue du Bois Saint Jean 15/1
BCE / VAT: BE 0521.816.349
On May 10, 2016 the USPTO issued a patent to Syngulon for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.
On January 29, 2019, USPTO issued a second patent to Syngulon covering the use of bacteriocin/immunity for the controlled growth of microorganisms.
Other patents: CN ZL 201480057387.2 + EP3035802B1 + BR112016003533-0 + IN389267
These issued patents are part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive base.
With support from the Wallonia Region of Belgium.
Other patent applications covering Syngulon’s technologies have been filed with USPTO or EPO in 2017, 2018, 2020, 2021 and 2022.